Peer-Support Groups Were Right, Guidelines Were Wrong: Dr. Mark Horowitz on Tapering Off Antidepressants
In an interview with MIA, Dr. Horowitz discusses his recent article on why tapering off antidepressants can take months or even years.
Researchers examine psychiatrist-client interactions and find that clients are often left with few opportunities to make explicit requests to change their medication regimen.
A new article in Lancet Psychiatry finds that slower tapering of SSRIs is better for preventing antidepressant withdrawal effects.
European citizens from 27 different countries will soon go to the polls to elect their representatives in the European Parliament for the next five years. As an advocacy organisation, we see those elections as an opportunity to call on current and future European leaders and policymakers to bring mental health to the heart of European policies.
“Converging lines of evidence now suggest that depression—a common comorbidity in the setting of chronic pain—may in some patients represent an unrecognized yet potentially reversible harm of opioid therapy.”
Researchers question the overstated results of a large antidepressant meta-analysis and point to cultural pressures to turn to these drugs for a quick fix.
Researchers identify simple ways for clinicians to begin deprescribing conversations.
John Ioannidis, a leading expert on research methods, takes a critical look at the way professional societies write treatment guidelines.
Dr. Dainius Pūras argues that the status quo in mental health treatment is no longer acceptable and demands political action to promote human rights.
Attempting to locate the mechanisms of psychiatric disorder is a step in the wrong direction and fails to challenge potentially unjust social practices.
A new paper explores how the disputed nature of psychiatric knowledge influences public perceptions and debates within the field of mental health.
A new study examines the benefits of collaborating with mental health consumers in research.
A new study has found that children and adolescents taking a high dose of antipsychotics are almost twice as likely to die of any cause than children on other types of medications.
An international group of researchers, including several with financial ties to manufacturers of antidepressants, explore possible explanations for why long-term users of antidepressants become chronically depressed.
In a MIA survey of people who had been patients in mental hospitals, nearly 500 respondents told of an experience that was often traumatic, and frequently characterized by a violation of their legal rights, forced treatment with drugs, and physical or sexual abuse. Only 17% said they were “satisfied” with the “quality of the psychiatric treatment” they received.
Benzodiazepine prescription practices may be in response to an epidemic of distress, rather than being used to treat specific mental health diagnoses.
Researchers discuss the evidence that antipsychotic medications may cause brain atrophy in children, whose brains are still developing.
Reforming the process of real informed consent can be brought to the horizon sooner rather than later if we have a solid idea of what the provision of truthful, unbiased research-based information about psychiatric medications should look like. Our upcoming series of webinars for 2019 will focus on just that.
Between 2007 and 2016, the FDA identified 776 herbal supplements containing active, unapproved pharmaceutical chemicals.
Psychiatrist and psychologist outline pharmacological and psychotherapeutic strategies for discontinuing antidepressants.
A recent Cochrane review has found that serious adverse events occur for about 1% of children and adolescents treated with Ritalin.
55 Steps is a new film based on a true story that centers around two women: Collette, a lawyer with a tendency to work long hours, and Eleanor, who has spent far too much time incarcerated in hospitals. Over the course of five years, Collette fights for Eleanor’s right to choose whether or not she takes psychiatric drugs. This film is imperfect, but its importance can’t be ignored.
New research suggests that clinicians should exercise caution prescribing SNRIs as first-line treatment for mood and anxiety disorders.
Prominent researchers conduct a review of antidepressant withdrawal incidence, duration, and severity. Results lead to call for new clinical guidelines.
A new study finds that sponsors of clinical trials in the EU continue to fail at reporting their results as required by recent legislation.